Intensive blood suger control in type 2 diabetes: Results of recent interventional trials (ADVANCE, VA Diabetes Trial and ACCORD);Contrôle glycémique intensif et diabète de type 2:résultats des etudes d'intervention récentes (ADVANCE, VA Diabetes Trial et ACCORD)

Sang Thrombose Vaisseaux

Volumn 21, Issue 1, 2009, Pages 15-22

  Guillausseau, Pierre Jean ^a   Virally, Marie ^a   Kevorkian, Jean Philippe ^a   Meas, Taly ^a   Laloi Michelin, Marie ^a   Ambonville, Catherine ^a   Bitu, Julie ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

ACCORD; ADVANCE; Hba1c intensive glycemic control; Intervention study; Microangiopathy; Normoglycemia; Type 2 diabetes; VA DT

Indexed keywords

GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C;

BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; COMORBIDITY; DIABETES CONTROL; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE SEVERITY; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART DEATH; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LIFE EXPECTANCY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; SHORT SURVEY;

EID: 61449242070     PISSN: 09997385     EISSN: 19506104     Source Type: Journal    
DOI: 10.1684/stv.2009.0353     Document Type: Short Survey

References (28)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 ; 352 : 837-53.
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 ; 352 : 854-65.
3. Stratton IM, Adler AI, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complications in type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 ; 321 : 405-12.
4. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabet Res Clin Pract 1995 ; 28 : 103-17.
5. Schichiri M, Ohkubo Y, Kishikawa H, et al. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000 ; 23(Suppl. 2): B21-B29.
6. Wake N, Hisashige A, Katayama T, et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diab Res Clin Pract 2000 ; 48 : 201-10.
7. Abraira C, Levin S, Emanuele NV, et al. Glycemic control and complications in type 2 diabetes. Design of a feasibility trial. Diabetes Care 1992 ; 15 : 1560-71.
8. Abraira C, Emanuele NV, Colwell JA, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type 2 diabetes (VACSDM). Results of the feasibility trial. Diabetes Care 1995; 18:1113-23.
9. Abraira C, Colwell JA, Nuttall F, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility trial. Veterans Affairs Cooperative Study on glycemic control and complications in type 2 diabetes. Arch Intern Med 1997 ; 157 : 181-8.
10. Buse JB, Bigger JT, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007 ;99(12A): 21i-33i.
11. Gerstein HC, Riddle MC, Kendall DM, et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007 ; 99(12A) : 34i-43i.
12. Type 2 diabetes treatment: French recommendations for good practice. Afssaps-HAS. 2006. Diabetes Metab 2006 ; 32 : 643.
13. News ACCORD. Conference press kit. February 6, 2008. http://www.nhlbi. nih.gov/health/prof/hear/other/accord/.
14. The Action to Control Cardiovascular Risk in Diabetes study group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-59.
15. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes (the ADVANCE trial): a randomised controlled trial. Lancet 2007 ; 370 : 829-40.
16. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
17. ADVANCE Management Committee. Study rationale and design of ADVANCE: Action in Diabetes and VAscular disease-preterax and dia-micron MR controlled evaluation. Diabetologia 2001 ; 44 : 1118-20.
18. ADVANCE Collaborative Group. ADVANCE Action in diabetes and vascular disease: patient recruitment and characteristics of the study population at baseline. Diabet Med 2004 ; 22 : 882-8.
19. Stolk RP, Vingerling JR, Cruickshank JK, et al. Rationale and design of the ADREM study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus. Contemp Clin Trials 2007 ; 28 : 6-17.
20. Stolk RP, van Schooneveld MJ, Cruickshank JK, et al. Retinal lesions in patients of Caucasian and Asian origin with type 2 diabetes. Baseline results from the ADVANCE Retinal Measurements (ADREM) STUDY.Diabet Care 2008 ; 31 : 708-13.
21. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN, for the DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial-revisited. Diabetes 2008 ; 57 : 995-1001.
22. Abraira C, Duckwoth W, McCarren M, et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications 2003 ; 17 :314-22.
23. th Meeting of the American Diabetes Association. San Francisco 6-10 June 2008.
24. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004 ; 141 : 421-31.
25. Holman RR, Paul SJ, Bethel MA, et al. Ten-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 ; 359 :1577-89.
26. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes and Control Trial. Diabetes 1997 ; 46 :271-86.
27. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 ;356:2457-71.
28. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007 ; 356 : 2522-4.